Analysis of neurofibromatosis type 1 gene mutation in juvenile chronic myelogenous leukemia

Ichiro Watanabe, Takahiko Horiuchi, Nobuaki Hatta, Mitsuru Matsumoto, Kenichi Koike, Seiji Kojima, Shouichi Ohga, Shigeru Fujita

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The neurofibromatosis type 1 (NF1) gene has been considered to be a tumor suppressor gene, since the NF1 gene product downregulates the ras oncogene product (p21(ras)). In addition, children with NF1 show an increased incidence of myelogenous leukemia, including juvenile chronic myelogenous leukemia (JCML). We studied 8 Japanese JCML patients without NF1 for mutations in exons 21-36 of the NF1 gene by using polymerase chain reaction/single-strand conformation polymorphism analysis. This region was chosen because it includes two main hotspots in the NF1 gene as well as the functionally important domain, GTPase-activating protein-related domain, which mediates the downregulation of ras activity. One of the 8 JCML patients exhibited a G to T transversion at the third nucleotide of the codon GAG for Glu at amino acid residue 1699, which results in the heterozygous conversion to Asp (E1699D). This variation was detected neither in 65 healthy volunteers nor 50 NF1 patients. No other variations were detected in our JCML patients. We suggest that NF1 gene mutation does not occur frequently in JCML without NF1.

Original languageEnglish
Pages (from-to)22-25
Number of pages4
JournalActa Haematologica
Volume100
Issue number1
DOIs
Publication statusPublished - Aug 15 1998

Fingerprint

Juvenile Myelomonocytic Leukemia
Neurofibromatosis 1 Genes
Neurofibromatosis 1
Mutation
Oncogene Protein p21(ras)
Down-Regulation
Neurofibromin 1
Proto-Oncogene Proteins p21(ras)
GTPase-Activating Proteins
Myeloid Leukemia
Tumor Suppressor Genes
Codon
Exons
Healthy Volunteers
Nucleotides
Amino Acids
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Watanabe, I., Horiuchi, T., Hatta, N., Matsumoto, M., Koike, K., Kojima, S., ... Fujita, S. (1998). Analysis of neurofibromatosis type 1 gene mutation in juvenile chronic myelogenous leukemia. Acta Haematologica, 100(1), 22-25. https://doi.org/10.1159/000040858

Analysis of neurofibromatosis type 1 gene mutation in juvenile chronic myelogenous leukemia. / Watanabe, Ichiro; Horiuchi, Takahiko; Hatta, Nobuaki; Matsumoto, Mitsuru; Koike, Kenichi; Kojima, Seiji; Ohga, Shouichi; Fujita, Shigeru.

In: Acta Haematologica, Vol. 100, No. 1, 15.08.1998, p. 22-25.

Research output: Contribution to journalArticle

Watanabe, Ichiro ; Horiuchi, Takahiko ; Hatta, Nobuaki ; Matsumoto, Mitsuru ; Koike, Kenichi ; Kojima, Seiji ; Ohga, Shouichi ; Fujita, Shigeru. / Analysis of neurofibromatosis type 1 gene mutation in juvenile chronic myelogenous leukemia. In: Acta Haematologica. 1998 ; Vol. 100, No. 1. pp. 22-25.
@article{5def2cca065e4defba9cb3c8089a5b18,
title = "Analysis of neurofibromatosis type 1 gene mutation in juvenile chronic myelogenous leukemia",
abstract = "The neurofibromatosis type 1 (NF1) gene has been considered to be a tumor suppressor gene, since the NF1 gene product downregulates the ras oncogene product (p21(ras)). In addition, children with NF1 show an increased incidence of myelogenous leukemia, including juvenile chronic myelogenous leukemia (JCML). We studied 8 Japanese JCML patients without NF1 for mutations in exons 21-36 of the NF1 gene by using polymerase chain reaction/single-strand conformation polymorphism analysis. This region was chosen because it includes two main hotspots in the NF1 gene as well as the functionally important domain, GTPase-activating protein-related domain, which mediates the downregulation of ras activity. One of the 8 JCML patients exhibited a G to T transversion at the third nucleotide of the codon GAG for Glu at amino acid residue 1699, which results in the heterozygous conversion to Asp (E1699D). This variation was detected neither in 65 healthy volunteers nor 50 NF1 patients. No other variations were detected in our JCML patients. We suggest that NF1 gene mutation does not occur frequently in JCML without NF1.",
author = "Ichiro Watanabe and Takahiko Horiuchi and Nobuaki Hatta and Mitsuru Matsumoto and Kenichi Koike and Seiji Kojima and Shouichi Ohga and Shigeru Fujita",
year = "1998",
month = "8",
day = "15",
doi = "10.1159/000040858",
language = "English",
volume = "100",
pages = "22--25",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Analysis of neurofibromatosis type 1 gene mutation in juvenile chronic myelogenous leukemia

AU - Watanabe, Ichiro

AU - Horiuchi, Takahiko

AU - Hatta, Nobuaki

AU - Matsumoto, Mitsuru

AU - Koike, Kenichi

AU - Kojima, Seiji

AU - Ohga, Shouichi

AU - Fujita, Shigeru

PY - 1998/8/15

Y1 - 1998/8/15

N2 - The neurofibromatosis type 1 (NF1) gene has been considered to be a tumor suppressor gene, since the NF1 gene product downregulates the ras oncogene product (p21(ras)). In addition, children with NF1 show an increased incidence of myelogenous leukemia, including juvenile chronic myelogenous leukemia (JCML). We studied 8 Japanese JCML patients without NF1 for mutations in exons 21-36 of the NF1 gene by using polymerase chain reaction/single-strand conformation polymorphism analysis. This region was chosen because it includes two main hotspots in the NF1 gene as well as the functionally important domain, GTPase-activating protein-related domain, which mediates the downregulation of ras activity. One of the 8 JCML patients exhibited a G to T transversion at the third nucleotide of the codon GAG for Glu at amino acid residue 1699, which results in the heterozygous conversion to Asp (E1699D). This variation was detected neither in 65 healthy volunteers nor 50 NF1 patients. No other variations were detected in our JCML patients. We suggest that NF1 gene mutation does not occur frequently in JCML without NF1.

AB - The neurofibromatosis type 1 (NF1) gene has been considered to be a tumor suppressor gene, since the NF1 gene product downregulates the ras oncogene product (p21(ras)). In addition, children with NF1 show an increased incidence of myelogenous leukemia, including juvenile chronic myelogenous leukemia (JCML). We studied 8 Japanese JCML patients without NF1 for mutations in exons 21-36 of the NF1 gene by using polymerase chain reaction/single-strand conformation polymorphism analysis. This region was chosen because it includes two main hotspots in the NF1 gene as well as the functionally important domain, GTPase-activating protein-related domain, which mediates the downregulation of ras activity. One of the 8 JCML patients exhibited a G to T transversion at the third nucleotide of the codon GAG for Glu at amino acid residue 1699, which results in the heterozygous conversion to Asp (E1699D). This variation was detected neither in 65 healthy volunteers nor 50 NF1 patients. No other variations were detected in our JCML patients. We suggest that NF1 gene mutation does not occur frequently in JCML without NF1.

UR - http://www.scopus.com/inward/record.url?scp=0031875457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031875457&partnerID=8YFLogxK

U2 - 10.1159/000040858

DO - 10.1159/000040858

M3 - Article

C2 - 9691142

AN - SCOPUS:0031875457

VL - 100

SP - 22

EP - 25

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 1

ER -